EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Blood DNA methylation cytometry reveals survival‐associated immune profiles in advanced non‐small cell lung cancer immune checkpoint inhibitor therapy

Markus Kleinberger, Erwin Tomasich, Julia Maria Berger, Vincent Sunder‐Plassmann, Angelika Martina Starzer, Lynn Gottmann, Martin Korpan, Oskar Steinbrecher, Nikola Vladic, Cihan Ay, Helmuth Haslacher, Christoph Minichsdorfer and 5 more

Clinical and Translational Discovery · 2026-12 · 6 (6)

DOI: 10.1002/ctd2.70232 ↗

At a glance

Journal article in Clinical and Translational Discovery, published online on 2026-11-19. Written by Markus Kleinberger and 16 co-authors. 40 references. The full text is freely available (open access, CC BY 4.0). Funded by: Christian Doppler Forschungsgesellschaft.

AstrattDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Immune checkpoint inhibitors (ICIs) improved outcomes in advanced non‐small cell lung cancer (NSCLC), yet reliable blood‐based biomarkers remain lacking. Methods and material DNA Methylation‐based immune cell deconvolution (methylation cytometry) was used to retrospectively analyze blood samples drawn before initiation of ICI from patients with advanced NSCLC. Patients were prospectively enrolled in an observational biobanking program and treated with ICIs. Treatment response was assessed by centralized radiological review. Associations between methylation‐derived immune profiles and objective response (OR), progression‐free survival (PFS) and overall survival (OS) were evaluated using multivariable logistic and Cox regression models.

Results

A total of 75 patients with NSCLC were included in the cohort (median age 66 years, IQR 61–72; 47% female). OR occurred in 39% of evaluable patients ‐ no methylation‐derived immune cell profile was independently associated with OR. However, higher proportions of CD4+ T cells, memory and naïve CD4+ T cells, naïve CD8+ T cells and total lymphocytes were independently associated with prolonged PFS and OS, while elevated neutrophil fractions predicted inferior survival.

Conclusions

In our cohort of advanced NSCLC patients methylation cytometry showed potentially prognostic systemic immune features with clinical outcome parameter.

Funding

  • Christian Doppler Forschungsgesellschaft

Cite

APA

Kleinberger, M., Tomasich, E., Berger, J. M., Sunder‐Plassmann, V., Starzer, A. M., Gottmann, L., Korpan, M., Steinbrecher, O., Vladic, N., Ay, C., Haslacher, H., Minichsdorfer, C., Furtner, J., Preusser, M., Berghoff, A. S., Fuereder, T., & Heller, G. (2026). Blood DNA methylation cytometry reveals survival‐associated immune profiles in advanced non‐small cell lung cancer immune checkpoint inhibitor therapy. Clinical and Translational Discovery, 6(6). https://doi.org/10.1002/ctd2.70232

Vancouver

Kleinberger M, Tomasich E, Berger JM, Sunder‐Plassmann V, Starzer AM, Gottmann L, et al. Blood DNA methylation cytometry reveals survival‐associated immune profiles in advanced non‐small cell lung cancer immune checkpoint inhibitor therapy. Clinical and Translational Discovery. 2026;6(6). doi:10.1002/ctd2.70232

BibTeX
@article{Kleinberger2026,
  author = {Kleinberger, Markus and Tomasich, Erwin and Berger, Julia Maria and Sunder‐Plassmann, Vincent and Starzer, Angelika Martina and Gottmann, Lynn and Korpan, Martin and Steinbrecher, Oskar and Vladic, Nikola and Ay, Cihan and Haslacher, Helmuth and Minichsdorfer, Christoph and Furtner, Julia and Preusser, Matthias and Berghoff, Anna Sophie and Fuereder, Thorsten and Heller, Gerwin},
  title = {Blood DNA methylation cytometry reveals survival‐associated immune profiles in advanced non‐small cell lung cancer immune checkpoint inhibitor therapy},
  journal = {Clinical and Translational Discovery},
  year = {2026},
  volume = {6},
  number = {6},
  doi = {10.1002/ctd2.70232}
}
Start for free →